Medicare beneficiaries reviewing 2027 plan options this fall will need to parse complex benefit structures across dozens of insurers to determine which plan saves them money. A new analysis from HealthMetrix Research offers a data-driven answer by identifying 23 Medicare Advantage insurers earning its 2027 Senior Choice Gold Award.
The distinction is based on cost-sharing analysis across 45 states and Puerto Rico. Selection criteria combined two metrics: exceptional benefit value as measured by copayments, deductibles and premiums, alongside quality ratings from the Centers for Medicare & Medicaid Services (CMS). Roughly 80 percent of award recipients achieved at least 4-star CMS ratings.
The awardees include major players such as Humana, Devoted Health, Aetna and Alignment Health, operating across diverse markets from rural areas in Mississippi and Montana to dense urban corridors in Massachusetts and New Jersey. The geographic spread suggests that competitive pressure and benefit design improvements are reaching beyond coastal metropolitan centers.
However, the data also reveals structural challenges. HealthMetrix Research required plans to meet a 3.5-star minimum rating threshold, underscoring that most Medicare Advantage products cluster in the respectable-but-not-exceptional range. CMS star ratings measure everything from customer service response times to how well plans manage chronic conditions. A 3.5-star floor is significant considering that beneficiaries often have limited choice, especially in rural markets where one or two plans may dominate.
The emphasis on cost-sharing analysis reflects genuine beneficiary concerns. Inflation continues to squeeze out-of-pocket expenses regardless of income level, according to Alan Mittermaier, HealthMetrix Research president. For seniors on fixed incomes, the difference between a $15 copay and a $25 copay compounds across dozens of prescriptions annually. Part D drug benefits represent a moving target, as formulary changes from year to year can dramatically shift a plan's true cost for someone managing multiple chronic conditions.
The HealthMetrix analysis examined "core benefits and cost-sharing features approved by Medicare" using publicly available information as of plan filing deadlines. But actual out-of-pocket costs depend on variables the analysis adjusts for statistically: individual health status and actual healthcare utilization patterns. Two beneficiaries in the same plan face vastly different costs depending on which doctors they see, which medications they take and which hospitals they use.
The award recipients span multiple carrier types and market strategies. Large national players like Humana and Aetna compete alongside specialized carriers like Devoted Health, which has carved out market share through aggressive benefit design and supplemental offerings. Alignment Health, a regional player with growing footprint, appears on the list, suggesting competition isn't entirely dominated by the largest insurers.
The geographic distribution of award-winning plans shows coverage concentration in certain states while offering options in others. Some beneficiaries will find multiple 2027 Gold Award recipients available in their county; others may find none. This variation reflects how Medicare Advantage works: carriers file plans at the county level, and not all counties attract robust competition. Rural areas particularly struggle with limited choice.
HealthMetrix Research explicitly states it "neither recommends nor endorses specific Medicare Advantage plans." The award recognizes plans meeting objective criteria but doesn't attempt to predict which plan suits any individual beneficiary. A plan offering excellent value for someone with diabetes may include costly copays for someone managing heart disease.
The data supporting this year's awards derives from Medicare Plan Finder, the government's official comparison tool available at Medicare.gov. The specific cost-sharing analysis is posted on MedicareNewsWatch.com, allowing deeper exploration of how the award calculations work.
As beneficiaries enter the 2027 Medicare Advantage enrollment window, they should view this analysis as one input among many. Individual circumstances—which doctors accept which plans, whether specific medications appear on formularies and which hospitals and specialists are in-network—ultimately drive the best choice.
The persistence of plans like Humana and Aetna among award recipients reflects their scale and market sophistication. But the inclusion of regional players and specialty carriers suggests the Medicare Advantage market retains enough competition to reward plans investing in genuine beneficiary value.
